Evidence map›Paper›PMID 37426646›Full record

SynthesisFrontiers in immunology2023

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.

Hao Xu, Tengyun Li, Guoyi Shao, Weizhi Wang, Zhongyuan He, Jianghao Xu, Yawei Qian, Hongda Liu, Han Ge, Linjun Wang and 4 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Hao XuDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Tengyun LiDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guoyi ShaoDepartment of General Surgery, Jiangyin People's Hospital Affiliated to Nantong University, Wuxi, China.
Weizhi WangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhongyuan HeDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jianghao XuDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yawei QianDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hongda LiuDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Han GeDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Linjun WangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Diancai ZhangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Li YangDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Fengyuan LiDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zekuan XuDepartment of General Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Cancer Hospital · CNJiangsu Province Hospital · CNJiangyin People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recently, the use of immunochemotherapy in the treatment of advanced gastric cancer (GC) has been increasing and programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy has become the first-line treatment for advanced GC. However, few studies with small sample sizes have examined this treatment regimen to assess its effectiveness and safety in the neoadjuvant treatment phase of resectable local advanced GC. Materials and methods: Herein, we systematically searched PubMed, Cochrane CENTRAL, and Web of Science for clinical trials on neoadjuvant immunochemotherapy (nICT) in advanced GC. The primary outcomes were effectiveness [evaluated by major pathological response (MPR) and pathological complete response (pCR)] and safety [assessed by grade 3-4 treatment-related adverse events (TRAEs) and postoperative complications]. A meta-analysis of non-comparative binary results was performed to aggregate the primary outcomes. Direct comparative analysis was used to compare pooled results of neoadjuvant chemotherapy (nCT) with nICT. The outcomes emerged as risk ratios (RR). Results: Five articles with 206 patients were included, and all of them were from the Chinese population. The pooled pCR and MPR rates were 26.5% (95% CI: 21.3%-33.3%) and 49.0% (95% CI: 42.3%-55.9%), while grade 3-4 TRAEs and post-operative complication rates were 20.0% (95% CI: 9.1%-39.8%) and 30.1% (95% CI: 23.1%-37.9%), respectively. Direct comparison showed that with the exception of grade 3-4 TRAEs and postoperative complications, all outcomes including pCR, MPR, and R0 resection rate favoured nICT to nCT. Conclusion: nICT is a promising strategy for use as an advisable neoadjuvant treatment for patients with advanced GC in Chinese population. However, more phase III randomized controlled trials (RCTs) will be required to further consolidate the efficacy and safety of this regimen.

Indexed as

ImmunotherapyNeoadjuvant TherapyStomach NeoplasmsEast Asian PeopleHumansPilot ProjectsPostoperative Complicationsmeta – analysisneoadjuant chemotherapyneoadjuvant immunochemotherapyperioperative immunotherapyresectable advanced gastric cancer

Identifiers

PMID37426646
PMCPMC10326549
OpenAlexW4381930349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.